ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.710
+0.040 (2.40%)
May 27, 2025, 4:00 PM - Market closed
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 4.74M EUR in the quarter ending March 31, 2025, with 1.74% growth. This brings the company's revenue in the last twelve months to 19.63M, up 85.91% year-over-year. In the year 2024, ProQR Therapeutics had annual revenue of 19.55M with 196.41% growth.
Revenue (ttm)
19.63M EUR
Revenue Growth
+85.91%
P/S Ratio
7.24
Revenue / Employee
118,158 EUR
Employees
166
Market Cap
180.14M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.55M | 12.95M | 196.41% |
Dec 31, 2023 | 6.59M | 2.24M | 51.27% |
Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
Dec 31, 2021 | 2.38M | 1.35M | 131.10% |
Dec 31, 2020 | 1.03M | -904.00K | -46.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PRQR News
- 15 days ago - ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewsWire
- 19 days ago - ProQR Announces First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 25 days ago - ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewsWire
- 26 days ago - ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 - GlobeNewsWire
- 6 weeks ago - ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth - GlobeNewsWire
- 2 months ago - ProQR Announces Year End 2024 Operating and Financial Results - GlobeNewsWire
- 6 months ago - ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - GlobeNewsWire
- 7 months ago - ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewsWire